publication venue for
- Early-phase trial of IAP antagonist tolinapant and definitive radiation in cisplatin-ineligible patients with previously untreated, locally advanced head and neck cancer Free 2025
- Tumor microenvironment of previously irradiated recurrent head and neck squamous cell carcinoma in humans 2025
- Viral-vectored, gene-directed prodrug therapy (Gedeptin) in needleaccessible solid tumors Free 2025
- CD28-negative T cells from head and neck cancer patients are functionally frail but not senescent 2023
- Statin drugs have anti-tumor activity and enhance responses to anti-PD-1 therapy in preclinical models of head and neck cancer 2022
- Statin drugs have anti-tumor activity and enhance responses to anti-PD-1 therapy in preclinical models of head and neck cancer. 2022
- Senolytic drug ABT-263 enhances cisplatin- and TIL-induced cell death in vitro but has limited in vivo activity in preclinical models of head and neck cancer 2020
- Anti-tumor activity of cisplatin is enhanced by PD-1 blockade in preclinical models of head and neck squamous cell carcinoma 2017
- Novel dual cIAP1/XIAP antagonist ASTX660 activity in preclinical models of human papillomavirus(+) and (-) head and neck squamous cell carcinoma 2017
- PD-1 Status in CD8+ T Cells Associates with Survival and Anti-PD-1 Therapeutic Outcomes in Head and Neck Cancer 2017